Pacira BioSciences, Inc. provided preliminary revenue guidance for the first quarter of 2022. For the period, the company reported preliminary revenues of $157.4 to $158.4 million for the first quarter of 2022, compared with $119.0 million for the first quarter of 2021. ZILRETTA net product sales are expected to be between $23.0 million and $24.0 million for the first quarter of 2022, compared with $24.6 million for the first quarter of 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.95 USD | +2.67% | +4.05% | -20.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.12% | 1.25B | |
+33.25% | 699B | |
+24.97% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+14.72% | 236B | |
+4.87% | 198B | |
-10.27% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Pacira BioSciences, Inc. Provides Preliminary Revenue Guidance for the First Quarter of 2022